Mitochondrial peptides

The mitochondrial-peptide field is the most recently-emerging area of peptide therapeutics. Three classes of molecules occupy this category: MOTS-c and the broader family of mitochondrial-derived peptides (MDPs) discovered in the 2010s — small bioactive peptides encoded within mitochondrial DNA itself, secreted from mitochondria, and acting as endocrine-like signals on distant tissues; SS-31 / Elamipretide — the cardiolipin-stabilizing peptide that protects mitochondrial cristae structure under stress; and an emerging cluster including Humanin, SHLP1-6, and other MDPs less commonly used recreationally but mechanistically related.

These peptides operate on a different layer of biology than the receptor-binding peptides that dominate most of the corpus. Where Ipamorelin binds GHS-R1a, where Semaglutide binds GLP-1R, where PT-141 binds melanocortin-4 — these mitochondrial peptides act on mitochondrial-resident processes: oxidative phosphorylation efficiency, mitochondrial membrane integrity, cristae morphology, mitochondrial dynamics (fusion vs fission), and the signaling crosstalk between mitochondria and the cellular metabolic state. The receptor pharmacology that determines the dose-response logic for most peptides on this site is less applicable here; what matters is the mitochondrial-state-modulation logic, which is different.

This dossier surveys what each molecule does in the published literature, where the mechanism translates to clinical claim, and where the evidence base is — honestly — younger and less RCT-validated than the receptor-pharmacology peptides because the field itself is newer.